2026 Archive
215 articles from 2026
Multimodal Immunotherapy and Chemoradiotherapy Strategies in Locally Advanced Lung Cancer
TITLE: Multimodal Immunotherapy and Chemoradiotherapy Strategies in Locally Advanced Lung Cancer SUMMARY: Platinum-based concurrent chemoradiotherapy (cCRT) followed by consolidation immune-checkpoin...
FDA approves tucatinib with trastuzumab and pertuzumab for the maintenance treatment of HER2-positive breast cancer
The 2026 World Health Organization Classification of Tumors of Soft Tissue and Bone: 6th Edition
TITLE: 2026 WHO Classification of Soft Tissue and Bone Tumors (6th Edition): Key Diagnostic Updates and New Entities SUMMARY: The 6th edition of the World Health Organization (WHO) Classification of ...
Five-Year Survival Analyses on Non-Pathological Complete Response Esophageal Squamous Cell Carcinoma Patients After Neoadjuvant Regimens Plus Surgery: A Propensity Score Matching, Real-World Cohort Study
TITLE: Five-Year Survival Outcomes in Non-pCR Esophageal Squamous Cell Carcinoma: Neoadjuvant Immunochemotherapy vs Chemotherapy Alone SUMMARY: In a propensity score-matched real-world cohort study o...
Administering Antineoplastic Parenteral Cancer Therapy in the Patient's Home: Perspectives of Oncology Nurses-A Descriptive Qualitative Study
TITLE: Oncology Nurse Perspectives on Home Parenteral Cancer Therapy: Safety Concerns and Implementation Needs SUMMARY: A descriptive qualitative study evaluated the perspectives of hospital oncology...
Obesity in survivors of childhood cancer
TITLE: Overweight and Obesity Trajectories in Childhood Cancer Survivors: Risk Factors and Clinical Timeline SUMMARY: A historical cohort study evaluating 820 pediatric cancer survivors treated at a ...
Physical Activity and Risk of Liver Cancer: A Competing Risk Analysis
TITLE: Physical Activity Reduces Liver Cancer Incidence in Competing Risk Analysis: NIH-AARP Study SUMMARY: In a causal competing risk analysis of 263,184 participants from the NIH-AARP Diet and Heal...
Trends in Population-Level Mortality Rates for Deaths With Both Alzheimer's Disease and Cancer Recorded on Death Certificates Among U.S. Adults Aged 65 Years, 1999-2023
TITLE: Mortality Trends for Concurrent Alzheimer's Disease and Cancer in Older US Adults: 1999–2023 CDC WONDER Analysis SUMMARY: A population-based descriptive time-trend analysis using CDC WONDER mu...
Every VoiceCAN: the journey and contributions of a grassroots regional cancer advisory network
TITLE: Regional Cancer Advisory Model Expands Rural Patient Engagement Across Clinical Networks SUMMARY: Participation rates in cancer clinical trials remain persistently low across rural, regional, ...
Safety Profile of Chimeric Antigen Receptor T-cell Therapies in Diffuse Large B-cell Lymphoma: An Analysis of Real-World Adverse Event Reporting From the FDA Adverse Event Reporting System
TITLE: Liso-cel vs Axi-cel in Diffuse Large B-Cell Lymphoma: FAERS Real-World Analysis Identifies Lower Odds of CRS, ICANS, and Cytopenias SUMMARY: A real-world pharmacovigilance study evaluating dat...
Feasibility of a prospective real-time monitoring system capturing real-world data from elderly patients with acute myeloid leukemia
TITLE: Automated Prospective Real-World Data Capture Validated Against Clinical Trial Controls in Older AML Patients SUMMARY: An automated, prospective real-time monitoring system successfully extrac...
ESTRO consensus recommendations on total skin electron beam technique - Endorsed by ILROG
TITLE: ESTRO and ILROG Consensus Recommendations for Total Skin Electron Beam Therapy in Cutaneous T-Cell Lymphoma SUMMARY: Total skin electron beam therapy (TSEBT) is an established radiation therap...
Real-world utilization of immune checkpoint inhibitors in medicare-eligible patients with triple-negative breast cancer in the United States
TITLE: Real-World Adoption of PD-(L)1 Inhibitors in Medicare-Eligible Triple-Negative Breast Cancer SUMMARY: In a retrospective analysis assessing real-world oncology practice patterns, immune checkp...
Understanding return to work after breast cancer through real-world data linkage framework: a Luxembourg digital oncology use case
TITLE: Real-World Data Linkage Demonstrates 77% Return-to-Work Rate Following Breast Cancer SUMMARY: Evaluating return to work (RTW) among working-age women diagnosed with breast cancer requires the ...
Tozuleristide Fluorescence-Guided Resection of Gliomas: Results of a Phase II Investigator-Initiated Study
TITLE: Tozuleristide Near-Infrared Fluorescence in Glioma Resection: Phase II Diagnostic and Resection Outcomes SUMMARY: In a Phase II, investigator-initiated, nonrandomized clinical trial, researche...
Building Computable Guidelines and Clinical Decision Support Tools for Cervical, Breast and Colorectal Cancer Screening and Risk Management: A CDC Initiative Update
TITLE: CDC Initiative Develops Computable EHR Decision Support Tools for Cervical, Breast, and Colorectal Cancer Screening SUMMARY: Translating narrative clinical practice guidelines into routine cli...
Oral vitamin C supplementation in patients with clonal cytopenia of undetermined significance or lower-risk myeloid malignancies: Results from EVITA, a phase 2 randomized, placebo-controlled trial
TITLE: EVITA Trial: Oral Vitamin C in Clonal Cytopenia of Undetermined Significance and Lower-Risk Myeloid Malignancies SUMMARY: The phase 2 EVITA trial evaluated the clinical impact, biological acti...
Equity gaps in pulmonary nodule risk prediction for never-smokers: a real-world evidence-informed narrative review and policy analysis
TITLE: Pulmonary Nodule Risk Stratification and Lung Cancer Screening Gaps in Never-Smokers: Real-World Evidence Review SUMMARY: Current lung cancer screening guidelines and pulmonary nodule risk ass...
Few cancer survivors returned to oncology after primary care transition, cohort finds
TITLE: Primary Care Transition Safety in Cancer Survivors: Recurrence Rates and Re-Access Outcomes in a Retrospective Cohort Study SUMMARY: In a retrospective cohort study conducted at the Juravinski...
TALENTOP: Liver Resection Post-Atezolizumab/Bevacizumab Prolongs Time to Treatment Failure
TITLE: Phase 3 TALENTOP Trial: Liver Resection Post-Atezolizumab/Bevacizumab Prolongs Time to Treatment Failure in Advanced Hepatocellular Carcinoma SUMMARY: The multicentre, open-label, randomised p...
Fractional CO2 Vaginal Laser Therapy for GSM in Breast Cancer Survivors
TITLE: Session-Dependent Efficacy of Fractional CO2 Vaginal Laser Therapy for Genitourinary Syndrome of Menopause in Breast Cancer Survivors SUMMARY: Genitourinary syndrome of menopause (GSM) is a pr...
Population genomic screening cohort shows high satisfaction and follow-up care
TITLE: Population Genomic Screening for HBOC and Lynch Syndrome: Clinical Follow-Up and Longitudinal Patient Outcomes SUMMARY: An evaluation of the 'In Our DNA SC' population-wide genomic screening (...
STAT+: Moderna and Merck say mRNA cancer vaccine succeeded in late-stage melanoma trial
TITLE: Personalized mRNA Vaccine Intismeran Plus Pembrolizumab Slows Recurrence in Phase 3 Melanoma Trial SUMMARY: In a randomized Phase 3 clinical trial, adding the personalized mRNA neoantigen vacc...
Cost-Effectiveness of First-Line Immunotherapy Regimens in Advanced PD-L1-Positive TNBC
TITLE: Cost-Effectiveness of First-Line Immunotherapy Regimens in Advanced PD-L1-Positive Triple-Negative Breast Cancer SUMMARY: An exploratory cross-trial partitioned survival model evaluated the co...
Japanese Guidelines Support Geriatric Assessment to Mitigate Toxicity in Older Cancer Patients
TITLE: Japanese Guidelines Support Geriatric Assessment to Mitigate Pharmacotherapy Toxicity in Older Cancer Patients SUMMARY: The Japanese Society of Medical Oncology and the Japanese Society of Cli...
Targeted total neoadjuvant therapy trial yields 40% complete response in rectal cancer
TITLE: Biomarker-Driven Total Neoadjuvant Therapy in High-Risk Rectal Cancer: Phase 2 TRAINER Study SUMMARY: The single-center, multicohort phase 2 TRAINER trial evaluated a personalized, biomarker-d...
Belinostat shows 30.5% response rate in relapsed refractory T-cell lymphoma cohort
TITLE: Real-World Outcomes of Belinostat in Relapsed or Refractory T-Cell Lymphomas: A Turkish Multicenter Study SUMMARY: In a retrospective multicenter study conducted by the Lymphoma Study Group of...
CDCP1-targeted antibody-drug conjugates and immunocytokines for cancer therapy
TITLE: Preclinical Efficacy of CDCP1-Targeted ADCs and Immunocytokines in Solid Tumors SUMMARY: CUB domain-containing protein 1 (CDCP1) is a tumor-associated surface antigen broadly expressed across ...
RADICAL Trial Evaluates Radium-223 Dichloride Plus Cabozantinib in Renal Cell Carcinoma
TITLE: RADICAL Trial Evaluates Radium-223 Dichloride Plus Cabozantinib in Renal Cell Carcinoma With Bone Metastases SUMMARY: The phase II randomized RADICAL trial (Alliance A031801), published ahead ...
G-oncoCOACH: Geriatric Assessment and Patient Coaching in Older Adults With Solid Tumors
TITLE: G-oncoCOACH: Comprehensive Geriatric Assessment and Patient Coaching in Older Adults With Solid Tumors SUMMARY: The G-oncoCOACH study evaluates secondary endpoints, including treatment-related...
Izalontamab Brengitecan Evaluated in Extensive-Stage Small Cell Lung Cancer Phase Ib Trial
TITLE: Izalontamab Brengitecan Evaluated in Extensive-Stage Small Cell Lung Cancer Phase Ib Trial SUMMARY: Izalontamab brengitecan (Iza-Bren) is a first-in-class bispecific antibody-drug conjugate (A...
Exercise Interventions and Quality of Life in Older Adults With Cancer
TITLE: Exercise Interventions and Quality of Life in Older Adults With Cancer: A Systematic Review and Meta-Analysis SUMMARY: A systematic review and meta-analysis published in the Journal of Geriatr...
Management of older adults with colorectal cancer – The state-of-the-art in 2026
TITLE: Management of Older Adults With Colorectal Cancer: 2026 State-of-the-Art Review SUMMARY: A state-of-the-art review on the management of older adults with colorectal cancer was published in the...
Integrating General Practice into Oncological Decision-Making for Frail Patients
TITLE: Integrating General Practice into Oncological Decision-Making for Frail Patients SUMMARY: A framework published in the Journal of Geriatric Oncology outlines a strategy for integrating general...
Systemic Treatment of Ovarian Cancer Recurrence: ASCO Living Guideline, Version 2026.1.0
TITLE: ASCO Updates Living Guideline Version 2026.1.0 on Systemic Treatment for Recurrent Ovarian Cancer SUMMARY: The American Society of Clinical Oncology (ASCO) has published Version 2026.1.0 of it...
Consensus research priorities in geriatric oncology: A Delphi study
TITLE: Consensus Research Priorities in Geriatric Oncology: Insights From a Delphi Study SUMMARY: A Delphi expert consensus study published in the Journal of Geriatric Oncology identified core resear...
Predicting Perioperative FLOT Outcomes in Resectable Gastric and GEJ Adenocarcinoma
TITLE: Predicting Perioperative FLOT Outcomes in Resectable Gastric and GEJ Adenocarcinoma via Pathologic and Molecular Features SUMMARY: A real-world retrospective cohort study published in the Euro...
COG AAML1831 Phase III Trial: CPX-351 vs Standard Induction Therapy in De Novo Pediatric AML
TITLE: COG AAML1831 Phase III Trial: CPX-351 vs Standard Induction Therapy in De Novo Pediatric AML SUMMARY: The Children's Oncology Group reported findings from AAML1831, a Phase III clinical trial ...
Prior-guided multi-expert consensus fusion for multi-center thyroid nodule classification
TITLE: AI-Driven Multi-Center Thyroid Nodule Classification via Multi-Expert Consensus Fusion SUMMARY: This study, published in Artificial Intelligence in Medicine, introduces a prior-guided multi-ex...
DPYD-Guided Metronomic Capecitabine and Vinorelbine in Metastatic HER2-Negative Breast Cancer
TITLE: DPYD-Guided Metronomic Capecitabine and Vinorelbine in Metastatic HER2-Negative Breast Cancer: Real-World Analysis SUMMARY: This real-world retrospective study, published in JCO Precision Onco...
Long-Term Overall Survival in BRAF V600–Mutant Advanced Melanoma: COMBI-I
TITLE: Long-Term Overall Survival with Spartalizumab, Dabrafenib, and Trametinib in BRAF V600–Mutant Advanced Melanoma: COMBI-I Findings SUMMARY: The COMBI-I study, published in the Journal of Clinic...
Phase III trial updates efficacy and safety of neoadjuvant Daromun in melanoma
TITLE: Neoadjuvant Intralesional Daromun (L19IL2/L19TNF) in Resectable Locally Advanced Melanoma: PIVOTAL Phase III Trial Update SUMMARY: The PIVOTAL Phase III trial investigated the efficacy and saf...
Adjusting PSA density thresholds optimizes prostate cancer diagnosis, study finds
TITLE: MR-PROPER Study: Optimizing PSA Density Thresholds for MRI-Directed Prostate Cancer Diagnosis SUMMARY: The community-based, multicentre MR-PROPER study, published in European Urology Oncology,...
HRD Testing and MYC Amplification in BRCA-Wild-Type High-Grade Serous Carcinoma
TITLE: HRD Testing Utility and MYC Amplification as a Surrogate Marker in BRCA-Wild-Type High-Grade Serous Carcinoma SUMMARY: This research evaluates the real-world application of homologous repair d...
Drug exposure definitions reported in real-world evidence studies on oncology medicines in patients with colorectal cancer: a scoping review
TITLE: Standardizing Drug Exposure Definitions in Colorectal Cancer Real-World Evidence: A Scoping Review SUMMARY: Published in ESMO Real World Data and Digital Oncology, this scoping review evaluate...
ASCO updates living guideline on stage IV NSCLC with driver alterations
TITLE: ASCO Living Guideline Update 2026.3.2: Stage IV NSCLC With Driver Alterations SUMMARY: This update (Version 2026.3.2) from the American Society of Clinical Oncology (ASCO), published in the Jo...
5-Year Results of First-Line Nivolumab Combinations in Advanced Esophageal Squamous Cell Carcinoma
TITLE: 5-Year Results of First-Line Nivolumab Combinations in Advanced Esophageal Squamous Cell Carcinoma: CheckMate 648 SUMMARY: The CheckMate 648 trial evaluated the long-term clinical outcomes of ...
Treatment of Multiple Myeloma: ASCO Living Guideline, Version 2026.1.1
TITLE: ASCO Living Guideline Update for Multiple Myeloma Treatment: Version 2026.1.1 SUMMARY: The American Society of Clinical Oncology (ASCO) has released Version 2026.1.1 of its living guideline fo...
SKYSCRAPER-01: First-Line Tiragolumab and Atezolizumab in PD-L1–High NSCLC
TITLE: SKYSCRAPER-01: First-Line Tiragolumab and Atezolizumab in PD-L1–High NSCLC SUMMARY: The SKYSCRAPER-01 trial investigated the clinical application of dual checkpoint inhibition using tiragoluma...
Endometrial Cancer by ERBB2 Amplification (ERBB2amp) Status: Differences in Molecular Subtypes, Ancestry, and Real-World Outcomes
TITLE: ERBB2 Amplification in Endometrial Cancer: Impact on Molecular Subtypes and Real-World Outcomes SUMMARY: This research evaluates the clinical significance of ERBB2 (HER2) amplification in endo...
Trial provides 5-year update on intismeran autogene plus pembrolizumab in melanoma
TITLE: Adjuvant Intismeran Autogene Plus Pembrolizumab in High-Risk Melanoma: 5-Year KEYNOTE-942 Update SUMMARY: The randomized Phase IIb KEYNOTE-942 study provides a 5-year update on the combination...
Breast Cancer Follow-Up and Surveillance After Primary Treatment: ASCO Guideline Update
TITLE: ASCO Clinical Practice Guideline Update: Breast Cancer Follow-Up and Surveillance After Primary Treatment SUMMARY: The American Society of Clinical Oncology (ASCO) has released an updated clin...
AI-HOPE: Multicenter Real-World Registry Integrating AI for Metastatic NSCLC
TITLE: AI-HOPE: Multicenter Real-World Registry Integrating AI for Metastatic NSCLC SUMMARY: The AI-HOPE (Artificial Intelligence-based Health Outcomes and Patient Experience) registry is a multicent...
NMPA and Zhejiang Society Establish AI Dataset Standards for Cervical Cytology
TITLE: NMPA and Zhejiang Society Establish AI Dataset Standards for Cervical Cytology SUMMARY: The Zhejiang Society for Mathematical Medicine, in collaboration with the National Medical Products Admi...
WOMBAT Phase 2 Trial: Bipolar Androgen Therapy for nmCRPC Progressing on Darolutamide
TITLE: WOMBAT Phase 2 Trial: Bipolar Androgen Therapy for nmCRPC Progressing on Darolutamide SUMMARY: The WOMBAT (ANZUP 2201) trial is a phase 2, single-arm clinical study evaluating the use of Bipol...
Feasibility and Impact of Pharmacist Medication Reviews in Geriatric Oncology Clinics
TITLE: Feasibility and Impact of Pharmacist Medication Reviews in Geriatric Oncology Clinics SUMMARY: This study, published in the Journal of Geriatric Oncology, examines the role and feasibility of ...
Real-World Registry Data for Adjuvant Pembrolizumab in High-Risk Renal Cell Carcinoma
TITLE: Real-World Registry Data for Adjuvant Pembrolizumab in High-Risk Renal Cell Carcinoma SUMMARY: This study, published in European Urology Oncology, evaluates real-world data regarding the use o...
Real-World Adherence to EAU Guidelines for NMIBC Management and Impact on Oncological Outcomes
TITLE: Real-World Adherence to EAU Guidelines for NMIBC Management and Impact on Oncological Outcomes SUMMARY: This research, published in European Urology Oncology, examines the implementation of Eu...
Irinotecan Added to Preoperative Chemoradiotherapy for High-Risk Rectal Cancer
TITLE: Irinotecan Added to Preoperative Chemoradiotherapy for High-Risk Rectal Cancer: ARISTOTLE Trial Results SUMMARY: The phase 3 ARISTOTLE trial, a multicentre, open-label, randomised controlled s...
SUPREMO Trial: 5-Year Quality-of-Life and Chest Wall Toxicity Following Postmastectomy Radiotherapy
TITLE: SUPREMO Trial: 5-Year Quality-of-Life and Chest Wall Toxicity Following Postmastectomy Radiotherapy SUMMARY: The phase 3 randomized controlled SUPREMO trial evaluated the 5-year quality-of-lif...
Real-World Study of the Implementation of Early and Systematic Palliative Care for Advanced Colorectal Cancer Care—The Palliative Care Early and Systematic Project
TITLE: Real-World Implementation of Early Palliative Care in Advanced Colorectal Cancer: The PALES Project SUMMARY: The Palliative Care Early and Systematic (PALES) project is a real-world study focu...
TITLE: Safety and Management of Inavolisib Plus Palbociclib-Fulvestrant in PIK3CA-Mutated HR+/HER2- Advanced Breast Cancer: INAVO120 Phase III Analysis SUMMARY: The Phase III INAVO120 trial evaluated...
Patient-reported outcomes in BRUIN CLL-321: A randomized phase 3 trial comparing pirtobrutinib to investigators choice of idelalisib plus rituximab or bendamustine plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma in the post-cBTKi setting
TITLE: Pirtobrutinib vs Standard Care for R/R CLL/SLL: Patient-Reported Outcomes From the BRUIN CLL-321 Trial SUMMARY: The Phase 3 BRUIN CLL-321 trial evaluated the clinical impact of pirtobrutinib, ...
FDA Expands Pembrolizumab and Enfortumab Vedotin Approval for All Neoadjuvant MIBC Patients
TITLE: FDA Expands Pembrolizumab and Enfortumab Vedotin Approval for All Neoadjuvant MIBC Patients SUMMARY: The FDA has expanded the approved indication for pembrolizumab (Keytruda) in combination wi...
FDA approves Jideytro for previously treated ROS1-positive NSCLC
TITLE: FDA Approves Zidesamtinib (Jideytro) for Pretreated ROS1-Positive Advanced NSCLC SUMMARY: The FDA has approved zidesamtinib (Jideytro, GSK) for adults with locally advanced or metastatic ROS1-...
Real-World Burden and Management of Late Genitourinary Toxicity After Prostate Radiotherapy: Insights from IRRADIaTE, the Italian Registry of Radiotherapy-Associated Disorders and Urological Treatment & Evaluation
TITLE: Management of Late Genitourinary Toxicity After Prostate Radiotherapy: Insights from the IRRADIaTE Registry SUMMARY: The IRRADIaTE (Italian Registry of Radiotherapy-Associated Disorders and Ur...
Magrolimab Plus Azacitidine Versus Placebo Plus Azacitidine in Patients With Untreated Higher-Risk Myelodysplastic Syndromes: The Phase III ENHANCE Study
TITLE: Phase III ENHANCE Trial: Magrolimab Plus Azacitidine Fails to Improve Outcomes in Higher-Risk MDS SUMMARY: The Phase III ENHANCE study, published in the Journal of Clinical Oncology, investiga...
Targeted Multidisciplinary Continuous Improvement Process Reduces Time to Breast Cancer Surgery with Immediate Reconstruction
TITLE: Multidisciplinary Quality Improvement Reduces Time to Breast Cancer Surgery with Immediate Reconstruction SUMMARY: A retrospective cohort study involving 3,324 patients evaluated the impact of...
FDA Greenlights Next-Generation ROS1 Inhibitor for Lung Cancer
TITLE: FDA Approves Zidesamtinib for Pretreated Advanced ROS1-Positive NSCLC SUMMARY: The FDA has granted approval to zidesamtinib (Jideytro), a next-generation ROS1 inhibitor, for the treatment of a...
AdvanTIG-302: Phase 3 Study of Ociperlimab (Anti-TIGIT) + Tislelizumab (Anti-PD-1) Versus Pembrolizumab in Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer With PD-L1 50
TITLE: AdvanTIG-302: Ociperlimab Plus Tislelizumab Fails to Improve OS in PD-L1 High NSCLC SUMMARY: The Phase 3 AdvanTIG-302 trial investigated whether the addition of ociperlimab, an anti-TIGIT anti...
Perioperative therapy in muscle-invasive bladder cancer: real-world evidence from the MINOTAURO study
TITLE: Real-World Perioperative Management and Outcomes in Muscle-Invasive Urothelial Cancer: The MINOTAURO Study SUMMARY: The multicenter, retrospective MINOTAURO study analyzed real-world periopera...
Next-Generation Sequencing Consensus Guidelines for Sarcoma: Progress, Gaps, and the Path Forward
TITLE: Consensus Guidelines for Next-Generation Sequencing (NGS) in Sarcoma Management SUMMARY: New consensus guidelines for the application of next-generation sequencing (NGS) in sarcoma have been p...
[Articles] Systemic therapy, gastrectomy, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy versus systemic therapy alone for gastric cancer with limited peritoneal metastases (PERISCOPE II): final results of a multicentre, randomised, controlled, phase 3 trial after an unplanned commissioned interim analysis
TITLE: PERISCOPE II Trial: CRS plus HIPEC Fails to Improve Survival in Gastric Cancer with Limited Peritoneal Metastases SUMMARY: The multicentre, randomised, phase 3 PERISCOPE II trial evaluated the...
Global Consensus on the Management of Primary Localized Chordoma
TITLE: Global Consensus Update: Clinical Management of Primary Localized Chordoma in Pediatric and Adult Patients SUMMARY: This Special Communication provides a comprehensive update and expansion of ...
Cognitive dysfunction associated with endocrine therapy and CDK4/6 inhibitors in breast cancer: A real-world analysis of the FDA Adverse Event Reporting System (FAERS) database
TITLE: Cognitive Dysfunction Risk with Endocrine Therapy and CDK4/6 Inhibitors: FAERS Database Analysis SUMMARY: This real-world study, published in the Journal of Geriatric Oncology, utilized the FD...
Diagnostic Accuracy of Liquid-Based Biomarkers for Detecting and Risk Stratifying Upper Tract Urothelial Cancers: A Diagnostic Test Systematic Review by the EAU Guidelines UTUC Panel
TITLE: Systematic Review of Liquid-Based Biomarkers for Upper Tract Urothelial Cancer Detection and Risk Stratification SUMMARY: This systematic review, conducted by the European Association of Urolo...
Effect of comprehensive geriatric assessment and supportive care on quality of life in older patients with cancer receiving curative treatment: The GOSPEL randomised controlled trial
TITLE: CGA-Guided Supportive Care Improves Longitudinal Quality of Life in Older Cancer Patients: The GOSPEL RCT SUMMARY: The GOSPEL randomized controlled trial investigated the impact of a specializ...
Final overall survival results from EORTC 1333/PEACE-3 trial of enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer
TITLE: Enzalutamide plus Radium-223 Increases Overall Survival in First-Line mCRPC: Final PEACE-3 Trial Results SUMMARY: The final overall survival (OS) analysis of the phase III EORTC 1333/PEACE-3 t...
Current Management Practices of De Novo Oligometastatic Breast Cancer: Real-World Data From a Physician Survey
TITLE: Management of De Novo Oligometastatic Breast Cancer: Real-World Physician Survey Results SUMMARY: This survey-based study analyzed the management preferences of 136 US medical oncologists rega...
Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trial
TITLE: Intensified Chemotherapy vs Standard Chemotherapy Plus Olaparib for Stage III HER2-Negative HRD Breast Cancer: The SUBITO Phase 3 Trial SUMMARY: The SUBITO phase 3 trial investigated whether i...
Comparative effectiveness of first-line ribociclib plus aromatase inhibitor versus palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer: A global real-world evidence study.
TITLE: First-Line Ribociclib vs. Palbociclib in HR+/HER2− Metastatic Breast Cancer: Real-World Comparative Effectiveness Study SUMMARY: This global real-world evidence study evaluates the comparative...
[Policy Review] Reirradiation for recurrent head and neck squamous cell carcinoma: international expert consensus recommendations endorsed by the Reirradiation Collaborative Group, the European Society for Radiotherapy and Oncology Reirradiation Focus Group, and the American Society for Radiation Oncology
TITLE: Expert Consensus Guidelines for Reirradiation in Recurrent Head and Neck Squamous Cell Carcinoma SUMMARY: This policy review presents international expert consensus recommendations for managin...
Refining Vascular Biomarker–Guided Risk Stratification for Cancer Therapy–Related Cardiac Dysfunction
TITLE: Vascular Biomarker-Guided Risk Stratification for Cancer Therapy-Related Cardiac Dysfunction SUMMARY: Published in JACC: CardioOncology, this research by Ze Xiang and Jian Wu addresses the ref...
Amivantamab in recurrent/metastatic HNSCC after checkpoint inhibitor and chemotherapy: pivotal results from the phase 1b/2 OrigAMI-4 study
TITLE: Amivantamab in Recurrent/Metastatic HNSCC Post-Immunotherapy: Phase 1b/2 OrigAMI-4 Trial Results SUMMARY: The phase 1b/2 OrigAMI-4 study (NCT06385080) evaluated the efficacy and safety of amiv...
Large language models in oncology: promise, pitfalls, and the path to real-world adoption
TITLE: Clinical Adoption and Implementation Frameworks for Large Language Models in Oncology SUMMARY: This review in ESMO Real World Data and Digital Oncology evaluates the clinical utility of large ...
[Articles] Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trial
TITLE: Aumolertinib Plus Chemotherapy Improves PFS in EGFR-Mutated Advanced NSCLC: Phase 3 AENEAS2 Trial SUMMARY: The AENEAS2 trial, a multicenter, randomized, open-label, phase 3 study, evaluated th...
Metastatic breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up†
TITLE: ESMO Clinical Practice Guidelines: Updated Recommendations for Metastatic Breast Cancer Management SUMMARY: The European Society for Medical Oncology (ESMO) has published updated Clinical Prac...
Real-world treatment durability and pain management in older adults with metastatic castration-resistant prostate cancer
TITLE: Real-World Treatment Durability and Pain Management in Older Adults with mCRPC SUMMARY: This research, published in the Journal of Geriatric Oncology, evaluates real-world treatment durability...
Impact of Trastuzumab on Survival Outcomes in Human Epidermal Growth Factor Receptor 2–Positive Biliary Tract Cancers: A Real-World Analysis From a High-Incidence Region (REAL TAB)
TITLE: Trastuzumab and Survival Outcomes in HER2-Positive Biliary Tract Cancers: REAL TAB Real-World Analysis SUMMARY: The REAL TAB study is a real-world analysis published in JCO Oncology Advances t...
Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, 2026.3.1
TITLE: ASCO Living Guideline Update: Therapy for Stage IV NSCLC With Driver Alterations SUMMARY: The American Society of Clinical Oncology (ASCO) has published an updated living guideline (version 20...
Phase 3 Trial Confirms Exercise Can Reverse Chemo Brain, Easing Cognitive Impairment Affecting 80 Percent of Cancer Patients
TITLE: Home-Based Walking Program Mitigates Chemotherapy-Induced Cognitive Impairment: Phase 3 EXCAP Trial Results SUMMARY: The Phase 3 EXCAP trial demonstrates that a structured home-based walking e...
Predictive Value of Prior Non–muscle-invasive Bladder Cancer for the Effectiveness of Neoadjuvant Chemotherapy in Localized Muscle-invasive Bladder Cancer: A Real-world Analysis of the BLADRAC Cohort
TITLE: Predictive Value of Prior NMIBC History for Neoadjuvant Chemotherapy Response in Muscle-Invasive Bladder Cancer SUMMARY: This real-world analysis of the BLADRAC cohort investigates whether a p...
[Articles] Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial
TITLE: Mezigdomide-Carfilzomib-Dexamethasone Improves PFS in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma: SUCCESSOR-2 Results SUMMARY: The Phase 3 SUCCESSOR-2 trial evaluated the effica...
Immunotherapy and surgical decision-making in Lynch syndrome–associated colorectal cancer: Implications for personalized management and guideline revision
TITLE: Immunotherapy and Surgical Decision-Making in Lynch Syndrome-Associated Colorectal Cancer SUMMARY: This publication in the European Journal of Surgical Oncology examines the evolving intersect...
Enhanced recovery after surgery (ERAS®) society guidelines for gynecologic oncology: 2026 update
TITLE: 2026 ERAS Society Clinical Practice Guidelines for Gynecologic Oncology Update SUMMARY: The Enhanced Recovery After Surgery (ERAS®) Society has published its 2026 updated clinical practice gui...
Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer: ASCO Guideline Clinical Insights
TITLE: ASCO Guideline Clinical Insights: Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer SUMMARY: This report, published in JCO Oncology Practice, provides clinical insights regarding the Ame...
Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆
TITLE: ESMO Clinical Practice Guidelines: Management of Advanced and Metastatic Prostate Cancer SUMMARY: This ESMO Clinical Practice Guideline provides an updated, evidence-based framework for the ma...
Endometrial cancer: A Society of Gynecologic Oncology evidence-based review and recommendations: Part I
TITLE: SGO Evidence-Based Clinical Recommendations for Endometrial Cancer: Part I SUMMARY: This article represents Part I of the Society of Gynecologic Oncology (SGO) evidence-based review and clinic...
Afatinib Versus Osimertinib for Non-Small Cell Lung Cancer With Uncommon EGFR Mutations: Real-World Outcomes
TITLE: First-Line Afatinib vs. Osimertinib in NSCLC with Uncommon EGFR Mutations: Real-World Efficacy and Subtype Considerations SUMMARY: This multicenter retrospective cohort study conducted across ...
Real-world comparison of avelumab maintenance versus pembrolizumab at progression after first-line platinum-based chemotherapy in metastatic urothelial cancer
TITLE: Real-World Comparison of Avelumab Maintenance vs. Second-Line Pembrolizumab in Metastatic Urothelial Cancer SUMMARY: This real-world study, conducted by the ProBCI Study Group and published in...
Real-world monitoring and clinical management of decreased platelet counts in patients with epithelial ovarian cancer who received first-line maintenance niraparib in the ACTIV1ZE study
TITLE: Real-World Management of Thrombocytopenia During First-Line Niraparib Maintenance in Epithelial Ovarian Cancer: The ACTIV1ZE Study SUMMARY: The ACTIV1ZE study investigates real-world clinical ...
Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer
TITLE: Zanidatamab and Tislelizumab Improve Survival in HER2-Positive Advanced Gastroesophageal Cancer: Phase 3 Results SUMMARY: In the phase 3 HERIZON-GEA-01 trial, the dual HER2-targeted bispecific...
An International Phase 4 Study of Lenvatinib and Sorafenib in Real-World Patients with Unresectable Hepatocellular Carcinoma: Final Analysis
TITLE: Lenvatinib Safety and Efficacy in Real-World Unresectable Hepatocellular Carcinoma: Final STELLAR Study Analysis SUMMARY: The Phase 4 STELLAR study, a prospective, non-interventional post-mark...
ESMO adaptation of Lines of Systemic Therapy (EnLiST): a consensus framework for standardising the designation of lines of therapy in solid tumours
TITLE: ESMO EnLiST Framework: Standardizing the Designation of Lines of Systemic Therapy in Solid Tumors SUMMARY: The European Society for Medical Oncology (ESMO) has developed the EnLiST (ESMO adapt...
Chinese expert consensus on prostate cancer testosterone management (2025 edition)
TITLE: 2025 Chinese Expert Consensus: Refined Testosterone Management in Prostate Cancer SUMMARY: The 2025 Chinese expert consensus on prostate cancer testosterone management addresses the increasing...
International Consensus on Axillary Staging After Neoadjuvant Chemotherapy in Node-positive Breast Cancer
TITLE: International Consensus Guidelines for Axillary Staging After Neoadjuvant Chemotherapy in Node-Positive Breast Cancer SUMMARY: This international consensus, published in the European Journal o...
Evolving Use of Circulating Tumor DNA for HPV+ Oropharyngeal Carcinoma: Consensus Recommendations From the California Head and Neck Consortium
TITLE: Consensus Recommendations for ctDNA Use in HPV-Positive Oropharyngeal Carcinoma SUMMARY: The California Head and Neck Consortium has developed consensus recommendations for the clinical applic...
AstraZeneca, Daiichi beat Gilead to first-line TNBC with FDA nod for Datroway
TITLE: FDA Approves Datroway as First TROP2 ADC for First-Line Triple-Negative Breast Cancer SUMMARY: The FDA has granted approval to AstraZeneca and Daiichi Sankyo’s Datroway for the first-line trea...
Publishing Prediction Models in Precision Oncology: A Summary of Guidelines and Recommendations
TITLE: Guidelines and Recommendations for Publishing Prediction Models in Precision Oncology SUMMARY: This article, published in JCO Precision Oncology, offers a detailed summary of the guidelines an...
Fulvestrant versus capecitabine as maintenance therapy in hormone receptor-positive, HER2-negative metastatic breast cancer after first-line chemotherapy (FAMILY): a multicenter, open-label, randomized, phase 3 trial
TITLE: Fulvestrant vs. Capecitabine Maintenance for HR+/HER2- Metastatic Breast Cancer: Phase 3 FAMILY Trial Results SUMMARY: The multicenter, open-label, randomized phase 3 FAMILY trial compared the...
ASCO: Merck, Kelun's sac-TMT ADC combo beats Keytruda by 65% on progression in first-line lung cancer
TITLE: Sac-TMT and Pembrolizumab Combination Reduces Progression Risk by 65% in First-Line PD-L1-Positive NSCLC SUMMARY: An abstract released ahead of the ASCO 2026 annual meeting highlights signific...
Detection of Homologous Recombination Repair Gene Mutations by Tumor Tissue and Circulating Tumor DNA Testing in Prostate Cancer in the Phase III PROpel Trial
TITLE: HRR Gene Mutation Detection via Tumor Tissue and ctDNA Testing in Prostate Cancer: Phase III PROpel Trial Analysis SUMMARY: This analysis from the Phase III PROpel trial, published in JCO Prec...
International Guideline Harmonization Group Recommendations for Breast Cancer Surveillance in Childhood, Adolescent, and Young Adult Cancer Survivors After Anthracyclines
TITLE: International Guidelines for Breast Cancer Surveillance in CAYA Cancer Survivors Post-Anthracyclines SUMMARY: The International Guideline Harmonization Group (IGHG) has issued clinical recomme...
Assessment of the Scandinavian guidelines on papillary thyroid cancer using the AGREE II instrument.
TITLE: AGREE II Assessment of Scandinavian Papillary Thyroid Cancer Clinical Guidelines SUMMARY: A research team led by Maria Sonesson O’Neill evaluated the quality of Scandinavian clinical practice ...
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals
TITLE: FDA Expands Enhertu Indications to Early Breast Cancer Adjuvant Therapy SUMMARY: The FDA has issued dual approvals for Enhertu (trastuzumab deruxtecan) for the treatment of early breast cancer...
Concurrent Versus Sequential Radiation Dose Escalation to the Surgical Cavity for Conservative Treatment of High-Risk Early Breast Cancer: NRG/RTOG 1005 Phase III Trial
TITLE: Concurrent vs Sequential Radiation Boost for High-Risk Early Breast Cancer: NRG/RTOG 1005 Phase III Trial Results SUMMARY: The NRG/RTOG 1005 phase III trial evaluated the efficacy and safety o...
Prolonged disease-free survival with immunotherapy combined with chemotherapy in a patient with advanced stage large cell neuroendocrine carcinoma of the uterus
TITLE: Dostarlimab and Multimodal Therapy for MMR-Deficient Uterine Large Cell Neuroendocrine Carcinoma SUMMARY: Large cell neuroendocrine carcinoma (LCNEC) of the uterus is a rare, aggressive malign...
Efficacy of immunotherapy and targeted therapy for unresectable hepatocellular carcinoma: analysis of survival curves
TITLE: First-Line Combination Therapies Superior in Unresectable Hepatocellular Carcinoma: A Parametric Survival Analysis of Phase III Trials SUMMARY: This systematic review and pooled analysis evalu...
Hong Kong Urological Association-Hong Kong Society of Uro-Oncology 2025 consensus on the management of locally advanced or metastatic renal cell carcinoma
TITLE: 2025 HKUA-HKSUO Consensus Guidelines: Management of Locally Advanced and Metastatic Renal Cell Carcinoma SUMMARY: The Hong Kong Urological Association (HKUA) and the Hong Kong Society of Uro-O...
FDA Advisors Split on Regimens for Breast, Prostate Cancers
TITLE: FDA Advisory Committee Split on New Regimens for Breast and Prostate Cancers SUMMARY: The FDA's Oncologic Drugs Advisory Committee (ODAC) recently evaluated new therapeutic regimens for breast...
Hepatocellular Carcinoma in the Immunotherapy Era: A SEER-Based Era Comparison Across the U.S. FDA Transition
TITLE: Hepatocellular Carcinoma Outcomes in the Immunotherapy Era: A SEER-Based Analysis of FDA Transition Impact SUMMARY: This study, published in the European Journal of Surgical Oncology, utilizes...
Review Duration and Therapeutic Value of Cancer Drugs Granted Priority Versus Nonpriority Review in the United States, European Union, and Switzerland (2010-2024)
TITLE: Priority vs. Nonpriority Review: Cancer Drug Approval Times and Therapeutic Value in the US, EU, and Switzerland (2010-2024) SUMMARY: Published in JCO Oncology Practice, this study investigate...
Impact of diabetes mellitus on treatment efficacy in patients with advanced pancreatic cancer: the Italian, multicenter, observational PANCAKE study
TITLE: Impact of Diabetes Mellitus on Treatment Efficacy in Advanced Pancreatic Cancer: The PANCAKE Study SUMMARY: The PANCAKE study is a multicenter, observational research effort conducted in Italy...
Real-world patterns of maintenance therapy after allogeneic transplant in older adults with acute myeloid leukemia: A Medicare cohort study
TITLE: Post-Transplant Maintenance Therapy Patterns in Older Adults with AML: A Medicare Cohort Study SUMMARY: A study published in the Journal of Geriatric Oncology examines the real-world utilizati...
Survey reveals ‘roadmap’ to improved pediatric oncology discourse
TITLE: Optimizing Prognostic Communication in Pediatric Oncology: A Multi-Stakeholder Survey Analysis SUMMARY: Prognostic communication in pediatric oncology is frequently complicated by the divergen...
Fall prevention in older patients with cancer: A call for action on behalf of the European Geriatric Medicine Society Special Interest Group on Gero-Oncology
TITLE: Fall Prevention in Older Patients with Cancer: EuGMS Gero-Oncology Call for Action SUMMARY: The European Geriatric Medicine Society (EuGMS) Special Interest Group on Gero-Oncology has issued a...
[Policy Review] International multisociety Delphi consensus for liver tumour thermal ablation: procedural and practice standards
TITLE: International Multisociety Standards for Liver Tumor Thermal Ablation: A Delphi Consensus Policy Review SUMMARY: Thermal ablation serves as a safer, minimally invasive, and cost-effective alte...
Noncompete agreements in job contracts: Knowledge and opinion of practicing gynecologic oncologist members of Society of Gynecologic Oncology
TITLE: Noncompete Agreements in Gynecologic Oncology: SGO Member Knowledge and Perspectives Survey SUMMARY: This study, published in Gynecologic Oncology, investigates the knowledge and perspectives ...
Celcuity’s gedatolisib beats Novartis’ Piqray in phase 3 breast cancer study
TITLE: Gedatolisib Outperforms Alpelisib in Phase 3 Breast Cancer Trial SUMMARY: Celcuity has announced that its investigational pan-PI3K/mTOR inhibitor, gedatolisib, successfully met the primary end...
FDA hands Pfizer, Arvinas’ Veppanu early approval for breast cancer subtype
TITLE: Veppanu (Pfizer, Arvinas) Receives Early FDA Approval for Breast Cancer Subtype SUMMARY: Veppanu, developed by Pfizer and Arvinas, has received early FDA approval from the FDA for a specific b...
Guidelines Can Be Lifesaving: The Vermont Model of Thromboprophylaxis Implementation
TITLE: Vermont Model for Thromboprophylaxis Implementation: Lifesaving Guidelines in Oncology Practice SUMMARY: The article, published in JCO Oncology Practice, examines the Vermont Model for impleme...
STAT+: FDA launches effort to speed up clinical trials, using AI
TITLE: FDA Initiatives: Real-Time Data Review and AI Integration to Accelerate Clinical Trials SUMMARY: The Food and Drug Administration (FDA) has announced new initiatives aimed at enhancing the eff...
NCCN publishes new patient guide for prostate cancer screening
TITLE: NCCN Publishes New Patient Guide Detailing Prostate Cancer Screening Evidence and Recommendations SUMMARY: The National Comprehensive Cancer Network® (NCCN®), an alliance of leading cancer cen...
Circulating Tumor DNA Assessment of Disease Response in Large B-Cell Lymphoma: Lisocabtagene Maraleucel Versus Autologous Stem Cell Transplantation Standard Therapy
TITLE: Circulating Tumor DNA for Disease Response in Large B-Cell Lymphoma: Lisocabtagene Maraleucel vs. Autologous Stem Cell Transplantation SUMMARY: This article, published in the Journal of Clinic...
EHR Burden in Oncology Is Taking a Toll. Is There a Fix?
TITLE: EHR Burden in Oncology: Impact on Patient Relationships and Documentation Challenges SUMMARY: Oncologists are experiencing a growing documentation burden and challenges with overflowing patien...
Merck KGaA, Remepy team up on software-enhanced hybrid drugs for rare tumors
TITLE: Merck KGaA and Remepy Partner to Develop AI-Driven Hybrid Drugs for Rare Tumors SUMMARY: German drugmaker Merck KGaA is collaborating with Israeli biotech Remepy to develop hybrid drugs. These...
Eli Lilly to Acquire Ajax Therapeutics in USD 2.3 Billion Cancer Drug Push
TITLE: Eli Lilly Acquires Ajax Therapeutics for Novel JAK2 Inhibitor AJ1-11095 in Myelofibrosis SUMMARY: Eli Lilly is set to acquire Ajax Therapeutics, expanding its oncology pipeline with AJ1-11095,...
Advances in anal cancer treatment: current standards, the role of immunotherapy and emerging strategies
TITLE: Anal Cancer Treatment: Current Standards, Immunotherapy, and Emerging Strategies SUMMARY: This article discusses current standards, the role of immunotherapy, and emerging strategies in the tr...
FDA lambasts Incyte over ‘misleading’ Niktimvo claims
TITLE: FDA Raises Concerns Over Incyte's Niktimvo Promotional Claims SUMMARY: The U.S. Food and Drug Administration (FDA) has expressed concerns regarding promotional claims made by Incyte for its ch...
Trial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4
TITLE: Recommendations for Prostate Cancer Clinical Trial Design and Objectives SUMMARY: This article, published in the Journal of Clinical Oncology (Ahead of Print), outlines recommendations from th...
UK real-world evidence on pembrolizumab and neoadjuvant chemotherapy for early-stage triple-negative breast cancer
TITLE: UK Real-World Evidence on Pembrolizumab and Neoadjuvant Chemotherapy for Early-Stage Triple-Negative Breast Cancer SUMMARY: This article presents UK real-world evidence regarding the use of pe...
Treatment Delays for Metastatic Breast Cancer Vary by Race
TITLE: Racial Disparities in Metastatic Breast Cancer Treatment Delays SUMMARY: A retrospective cross-sectional analysis investigated racial differences in treatment delays and presentation among pat...
Alternative medicine linked with worse survival in breast cancer
TITLE: Complementary and Alternative Medicine Use Associated with Worse Breast Cancer Survival SUMMARY: An evaluation of over 2 million women with breast cancer revealed that those treated with compl...
Decision-making performance of large language models vs. human physicians in challenging lung cancer cases: A real-world case-based study
TITLE: Large Language Models vs. Human Physicians: Decision-Making Performance in Challenging Lung Cancer Cases SUMMARY: This real-world case-based study investigated the decision-making performance ...
EMA Recommends Generic in Advanced/Metastatic Breast Cancer
TITLE: EMA Recommends Generic Palbociclib for HR+/HER2- Advanced/Metastatic Breast Cancer SUMMARY: The European Medicines Agency (EMA) has issued a recommendation for a generic version of palbociclib....
CAR T-cell therapy may prevent progression of smoldering myeloma
TITLE: CAR T-Cell Therapy Ciltacabtagene Autoleucel Shows Sustained Benefit in High-Risk Smoldering Myeloma, Preventing Progression SUMMARY: A phase 2 trial has demonstrated that chimeric antigen rece...
ONS/ASCO Guideline on the Management of Antineoplastic Extravasation
TITLE: ONS/ASCO Guideline: Evidence-Based Management of Antineoplastic Extravasation for Oncology Professionals SUMMARY: The Oncology Nursing Society (ONS) and the American Society of Clinical Oncolog...
An electronic geriatric assessment platform (eGAP) for older patients with cancer
TITLE: Electronic Geriatric Assessment Platform (eGAP) for Older Patients with Cancer: Optimizing Care SUMMARY: This article introduces an electronic geriatric assessment platform (eGAP) designed for ...
NICE Recommends Combination Treatment for Advanced NSCLC
TITLE: NICE Recommends First-Line Oral Dabrafenib/Trametinib for BRAF V600E-Mutated Advanced NSCLC SUMMARY: The National Institute for Health and Care Excellence (NICE) has published final draft guida...
Measurable Residual Disease Predicts Real-World AML Relapse
TITLE: Measurable Residual Disease Thresholds Predict Relapse in Real-World NPM1-Mutated AML, Informing Treatment Decisions SUMMARY: A recent real-world study has reinforced the prognostic significanc...
NEO-RT Organ Preservation Trial for Early Rectal Cancer: CCTG CO.32 Phase III Randomized Trial of Neoadjuvant Chemotherapy, Excision and Observation Versus Chemoradiotherapy
TITLE: NEO-RT Organ Preservation Trial for Early Rectal Cancer: CCTG CO.32 Phase III Randomized Trial of Neoadjuvant Chemotherapy, Excision and Observation Versus Chemoradiotherapy SUMMARY: This artic...
Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study
TITLE: CAPItello-281 Phase III: Investigating Capivasertib + Abiraterone in PTEN-Deficient Metastatic Hormone-Sensitive Prostate Cancer SUMMARY: This entry pertains to the CAPItello-281 Phase III stud...
STAT+: Replimune skin cancer drug that became FDA flashpoint is rejected again
TITLE: FDA Rejects Replimune's Experimental Oncolytic Virus for Advanced Melanoma, Again SUMMARY: The U.S. Food and Drug Administration (FDA) has issued a second rejection for Replimune Group's invest...
Clinical strategies for lymphoma management: Recommendations from the Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Consensus Conference 2025
TITLE: Bridging Gaps in Lymphoma Management: Expert Consensus on MCL, CLL, and DLBCL Strategies SUMMARY: The Bridging the Gaps (BTG) in Leukemia, Lymphoma and Multiple Myeloma Consensus Conference 202...
Is more always better? Low-dose pembrolizumab as a practical step toward more equitable triple-negative breast cancer care
TITLE: Optimizing Pembrolizumab Dosing for Triple-Negative Breast Cancer: Implications for Equitable Care SUMMARY: This analysis is based solely on the provided article title, as the full content was ...
Living Guidelines for Tumor-Agnostic Therapies: A Pathway to Next-Generation Cancer Treatment
TITLE: Clinical Guidelines for Tumor-Agnostic Therapies: Advancing Next-Generation Cancer Treatment SUMMARY: The provided article, published in JCO Precision Oncology, Volume 10, Issue 4, introduces t...
HosTIL territory: mapping the landscape of toxicity in TIL therapy
TITLE: Navigating Toxicity in Tumor-Infiltrating Lymphocyte (TIL) Therapy for Advanced Melanoma SUMMARY: Tumor-infiltrating lymphocyte (TIL) therapy has recently received US FDA and Health Canada appr...
Enhancing engagement in biobanking research among Black women with endometrial cancer
TITLE: Enhancing Biobanking Engagement in Black Women with Endometrial Cancer: Strategies and Impact SUMMARY: The provided information consists solely of a title, publication details, and author list ...
Geriatric oncology in 2040: Exploring potential realities and challenges. A diverse perspective
TITLE: Geriatric Oncology in 2040: Anticipating Future Realities and Clinical Challenges SUMMARY: This analysis is based solely on the provided title and author list, as the full article content was n...
How Much Is Enough? Ultra-Low Doses of Immunotherapy to Improve Access and Affordability
TITLE: Ultra-Low Dose Immunotherapy: Exploring Efficacy, Access, and Affordability in Oncology SUMMARY: This article from the Journal of Clinical Oncology, "Ahead of Print," explores the concept of us...
VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor–Positive/HER2−/PIK3CA Wild-Type Advanced Breast Cancer
TITLE: VIKTORIA-1 Trial Investigates Gedatolisib Combinations in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer SUMMARY: The VIKTORIA-1 trial is an "Ahead of Print" publication from the Journal of ...
[Articles] Pain and health-related quality-of-life outcomes with darolutamide in metastatic hormone-sensitive prostate cancer (ARANOTE): secondary and exploratory analyses of a multicentre, randomised, placebo-controlled, phase 3 trial
TITLE: Darolutamide Delays Pain Progression and Preserves Quality of Life in mHSPC: ARANOTE Phase 3 Secondary Analysis SUMMARY: Secondary and exploratory analyses of the multicenter, randomized, place...
Prospective Evaluation of the Cardiovascular Effects of BRAF and MEK Inhibitors in Patients With Melanoma
TITLE: Prospective Evaluation of Cardiovascular Effects of BRAF and MEK Inhibitors in Melanoma Targeted Therapy SUMMARY: BRAF and MEK inhibitors are cornerstone targeted therapies for patients with BR...
Brentuximab vedotin and dose attenuated chemoimmunotherapy for patients 75 years and older with diffuse large B-cell lymphoma with analysis of outcomes by frailty
TITLE: Brentuximab Vedotin and Dose-Attenuated Chemoimmunotherapy in Elderly DLBCL: Analyzing Outcomes by Frailty SUMMARY: This article investigates the efficacy and safety of a treatment regimen comb...
Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial
TITLE: Phase III TROPION-Breast02 Trial Investigating Datopotamab Deruxtecan in Untreated, Advanced Triple-Negative Breast Cancer SUMMARY: The TROPION-Breast02 trial is an international, open-label, r...
Oncology Drug Development: Challenges of Increasingly Available Therapies
TITLE: Oncology Drug Development: Navigating Challenges of Expanding Therapeutic Options SUMMARY: The provided article content is insufficient to generate a comprehensive summary that meets the specif...
STAT+: FDA backs proposals to entice pharma companies to test, make drugs domestically
TITLE: FDA Proposes Policies to Boost Domestic Drug Development and Manufacturing SUMMARY: The Food and Drug Administration (FDA) has outlined new policy proposals aimed at incentivizing the domestic ...
Is Progression-Free Survival 2 Ready for Prime Time in US Food and Drug Administration Regulatory Decision Making?
TITLE: Progression-Free Survival 2 (PFS2) as an FDA Regulatory Endpoint in Oncology: A Critical Evaluation** SUMMARY: This article from the Journal of Clinical Oncology critically evaluates the readin...
HER-2 gene alterations as biomarker in patients with metastatic colorectal cancer treated with FOLFIRI + cetuximab: findings from the CAPRI-2 GOIM study
TITLE: HER2 Gene Alterations as a Biomarker in Metastatic Colorectal Cancer Patients Treated with FOLFIRI and Cetuximab: The CAPRI-2 GOIM Study SUMMARY: The CAPRI-2 GOIM study investigates the potenti...
Randomized Phase III Trial for Evaluating the Efficacy of Adjuvant Abemaciclib in Patients With Locoregional Recurrence of Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer: JCOG2313, AURA Trial
TITLE: Adjuvant Abemaciclib in HR+/HER2- Breast Cancer with Locoregional Recurrence: JCOG2313 AURA Phase III Trial Protocol SUMMARY: This entry describes the protocol for JCOG2313, also known as the A...
FDA extends review of Orca Bio’s novel cell therapy for blood cancers
TITLE: FDA Extends PDUFA Date for Orca-T Cell Therapy in Blood Cancers SUMMARY: The U.S. Food and Drug Administration (FDA) has extended its target decision date for Orca Bio's investigational cell th...
Still reeling from FDA refusal, IO Biotech surrenders to bankruptcy
TITLE: Biotechnology Firm IO Biotech Declares Bankruptcy Following FDA Refusal of Investigational Therapy SUMMARY: IO Biotech, a biotechnology company, has announced its cessation of operations and de...
Development of a Classifier for Metabolic Subtypes of Nasopharyngeal Carcinoma to Guide Personalized Immunotherapy Strategies: Biomarker Analysis of the Phase III CONTINUUM and DIPPER Trials
TITLE: Metabolic Subtyping in Nasopharyngeal Carcinoma: A Novel Biomarker for Optimizing Immunotherapy in Phase III CONTINUUM and DIPPER Trials SUMMARY: Researchers have developed and validated a meta...
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial
TITLE: Long-Term Efficacy of First-Line Nivolumab plus Ipilimumab in Advanced Renal Cell Carcinoma: Final CheckMate 214 Analysis SUMMARY: The final analysis of the landmark Phase III CheckMate 214 tri...
Dizal's Zegfrovy clinches landmark phase 3 win in NSCLC subtype, setting up challenge to J&J's Rybrevant
TITLE: Oral Zegfrovy Achieves Positive Phase 3 Results in Non-Small Cell Lung Cancer Subtype, Poised to Compete with Rybrevant SUMMARY: Dizal has announced positive Phase 3 clinical trial results for ...
Regulatory tracker: BMS' Opdivo nabs triplet of FDA lymphoma endorsements
TITLE: FDA Grants Multiple Designations to Nivolumab (Opdivo) for Lymphoma Indications SUMMARY: The FDA has granted a series of regulatory endorsements to Bristol Myers Squibb’s nivolumab (Opdivo), a ...
OPTIMAL: A Multinational Phase III Study of Oral Paclitaxel (DHP107) versus Intravenous Weekly Paclitaxel in HER2-Negative Recurrent or Metastatic Breast Cancer
TITLE: Phase III OPTIMAL Trial: Oral Paclitaxel (DHP107) Demonstrates Non-Inferiority to Weekly IV Paclitaxel in HER2-Negative Metastatic Breast Cancer SUMMARY: The OPTIMAL study, a multinational Phas...
Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Phase III LEAP-010 Study
TITLE: First-Line Pembrolizumab Plus Lenvatinib for R/M Head and Neck Squamous Cell Carcinoma: Results from the Phase III LEAP-010 Study SUMMARY: The Phase III LEAP-010 study evaluated the efficacy an...
Comparison of treatment efficacy of targeted therapies approved in China for non-small cell lung cancer before and after the introduction of accelerated drug marketing registration procedures
TITLE: Impact of Accelerated Drug Marketing Registration Procedures on NSCLC Targeted Therapy Efficacy in China SUMMARY: A retrospective study evaluated the clinical efficacy and regulatory landscape ...
Prospective study of patients with immune checkpoint inhibitor-induced hepatitis; characterization of liver injury, outcome of therapy, and management of steroid-unresponsive and steroid-dependent hepatitis
TITLE: Management and Characterization of Grade 3-4 Immune Checkpoint Inhibitor-Induced Hepatitis: A Prospective Study SUMMARY: This prospective study (NCT04810156) investigated the clinical phenotype...
FDA approves first treatment for smoldering multiple myeloma
TITLE: FDA Approves Daratumumab-Hyaluronidase as First Treatment for High-Risk Smoldering Multiple Myeloma SUMMARY: The U.S. Food and Drug Administration (FDA) has granted approval for daratumumab and...
Biomarkers and Cardiotoxicity in Breast Cancer: A Step Forward and More Studies Needed
TITLE: Clinical Utility of Biomarkers for Monitoring Cardiotoxicity in Breast Cancer Patients SUMMARY: This analysis from *JACC: CardioOncology* evaluates the evolving role of cardiac biomarkers, spec...
Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer
TITLE: Trastuzumab Deruxtecan vs. Trastuzumab Emtansine for Residual HER2-Positive Early Breast Cancer: DESTINY-Breast05 Trial Results SUMMARY: The phase 3 DESTINY-Breast05 randomized clinical trial e...
Axitinib and Long-Acting Octreotide in Advanced Extrapancreatic Neuroendocrine Tumors: A Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trial (AXINET, GETNE 1107)
TITLE: Axitinib Combined With Octreotide LAR in Advanced Extrapancreatic Neuroendocrine Tumors: Results From the Phase III AXINET Trial SUMMARY: The AXINET (GETNE 1107) study, a multicenter, randomize...
Impact of nutritional risk screening on outcomes of first-line treatment in metastatic esophagogastric adenocarcinoma: a secondary analysis of the AIO-MATEO trial
TITLE: Nutritional Risk Screening as a Prognostic Indicator in Metastatic Esophagogastric Adenocarcinoma: AIO-MATEO Trial Analysis SUMMARY: This secondary analysis of the prospective, randomized AIO-M...
FDA freezes enrollment in MacroGenics cancer trial after patient death
TITLE: FDA Places Partial Clinical Hold on MacroGenics Phase 2 Lorigerlimab Trial Following Patient Fatality SUMMARY: The U.S. Food and Drug Administration (FDA) has implemented a partial clinical hol...
FDA Grants Full Approval to Encorafenib in Metastatic CRC
TITLE: FDA Grants Full Approval to Encorafenib-Cetuximab Combination for BRAF V600E-Mutant Metastatic Colorectal Cancer SUMMARY: The U.S. Food and Drug Administration (FDA) has transitioned the accele...
Acalabrutinib-venetoclax combination gets FDA nod for CLL
TITLE: FDA Approves Acalabrutinib-Venetoclax for First-Line CLL/SLL SUMMARY: The FDA has granted approval for the first all-oral, fixed-duration, first-line regimen for chronic lymphocytic leukemia (C...
Major Adverse Cardiovascular Events and Cardiac Dysfunction in Patients With Acute Leukemia: A Prospective Study
TITLE: Cardiovascular Events and Cardiac Dysfunction in Acute Leukemia: A Prospective Analysis SUMMARY: This prospective study investigated the incidence of major adverse cardiovascular events (MACE) ...
Effect of geriatric co-management on independence, quality of life, and severe toxicity in vulnerable older patients with cancer: Results of a randomized clinical trial
TITLE: Geriatric Co-Management Improves Independence and Reduces Toxicity in Vulnerable Older Cancer Patients SUMMARY: A randomized clinical trial investigated the impact of geriatric co-management on...
Trends of Authors' Conflicts of Interest in Clinical Trials Published in the Journal of Clinical Oncology: A Large Language Model–Assisted Longitudinal Study
TITLE: Trends in Conflicts of Interest in *JCO* Clinical Trials: A Large Language Model-Assisted Analysis SUMMARY: A longitudinal study utilizing a large language model (LLM) analyzed financial confli...
An overview of clinical trials in anal cancer 1999-2024
TITLE: Anal Cancer Clinical Trials: A 25-Year Overview (1999-2024) SUMMARY: This overview summarizes clinical trial activity in anal cancer from 1999 to 2024, providing a comprehensive landscape of re...
Agilent companion diagnostic lands FDA nod alongside Keytruda's latest cancer approval
TITLE: Agilent's Companion Diagnostic for Ovarian Cancer Gains FDA Approval Alongside Keytruda SUMMARY: The FDA has approved Agilent Technologies' companion diagnostic, the PD-L1 IHC 22C3 pharmDx, to ...
Patient-reported Quality of Life in PROFIT, a Phase 3 Randomized Clinical Trial Evaluating Moderately Hypofractionated Radiotherapy for Intermediate-risk Prostate Cancer
TITLE: Patient-Reported Quality of Life with Moderately Hypofractionated Radiotherapy for Intermediate-Risk Prostate Cancer SUMMARY: This Phase 3 randomized clinical trial, PROFIT, investigated patien...
Neoadjuvant Taxane Plus Trastuzumab and Pertuzumab With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: The Randomized Noninferiority Phase III neoCARHP Trial
TITLE: Neoadjuvant Carboplatin Integration in HER2-Positive Breast Cancer: Noninferiority of Taxane/Trastuzumab/Pertuzumab Regimen SUMMARY: The neoCARHP trial, a randomized noninferiority Phase III st...
Immunotherapy Regimen Approved for Recurrent Ovarian Cancer
TITLE: FDA Approves Pembrolizumab with Paclitaxel for PD-L1 Positive Recurrent Ovarian Cancer SUMMARY: The U.S. Food and Drug Administration (FDA) has granted accelerated approval for pembrolizumab (K...
Role of a Designated Pharmacist in Reducing Adverse Drug Reaction Rates and Preventing Potential Medication Errors in Hematology-Oncology: A Randomized Controlled Trial
TITLE: Pharmacist Intervention Reduces ADRs and Medication Errors in Hematology-Oncology: A RCT SUMMARY: This randomized controlled trial investigated the impact of a designated pharmacist on adverse ...
Final overall survival analysis and exploratory biomarker study from JUPITER-06: a randomized phase 3 trial of toripalimab plus chemotherapy in advanced esophageal squamous cell carcinoma
TITLE: Toripalimab Plus Chemotherapy in Advanced Esophageal Squamous Cell Carcinoma: Final Overall Survival and Biomarker Analysis from JUPITER-06 SUMMARY: The JUPITER-06 trial, a randomized phase 3 s...
Pretreatment Circulating Vascular Biomarkers Predict Cancer Therapy–Related Cardiac Dysfunction During HER2+ Breast Cancer Treatment
TITLE: Circulating Vascular Biomarkers Predict Cardiotoxicity in HER2+ Breast Cancer Therapy SUMMARY: A study published in JACC: CardioOncology investigated the utility of pretreatment circulating vas...
Establishing Oncological Safety of Autologous Fat Transfer for Total Breast Reconstruction: Results from the Multicentre BREAST-I and BREAST-II Trials
TITLE: Oncological Safety of Autologous Fat Transfer in Total Breast Reconstruction: BREAST-I and BREAST-II Trials SUMMARY: The multicenter BREAST-I and BREAST-II trials provide crucial evidence regar...
Tissue-Free Circulating Tumor DNA Assay and Patient Outcome in a Phase III Trial of FOLFOX-Based Adjuvant Chemotherapy (Alliance N0147)
TITLE: Circulating Tumor DNA (ctDNA) Predicts Recurrence and Survival in Stage III Colon Cancer Post-FOLFOX Adjuvant Chemotherapy SUMMARY: A prospective analysis from the Alliance N0147 phase III tria...
Chemoradiation and Image-Guided Brachytherapy Alone or in Combination With Protease Inhibitor (Nelfinavir Mesylate) in Stage III Cervical Cancer: Results From a Phase III Trial
TITLE: Nelfinavir Mesylate with Chemoradiation and Brachytherapy for Stage III Cervical Cancer: Phase III Trial Results SUMMARY: This Phase III clinical trial investigated the efficacy and safety of a...
Reduced Exercise Capacity in Breast Cancer Compared to HFpEF: Mechanistic Insights From Invasive Exercise Testing
TITLE: Invasive Exercise Testing Reveals Reduced Exercise Capacity in Breast Cancer Patients Compared to HFpEF SUMMARY: This study, published in JACC: CardioOncology, utilized invasive cardiopulmonary...
Spreading drug costs over the year may ease financial burden for Medicare cancer patients
TITLE: Medicare Prescription Payment Plan: Easing Financial Burden for Cancer Patients SUMMARY: The Medicare Prescription Payment Plan (M3P), an opt-in policy effective in 2025 under the Inflation Red...
Single-drug Exelixis aims to be top 5 solid tumor company in the US: CEO
TITLE: Exelixis Eyes Top-Tier Solid Tumor Market Position with Cabozantinib and Expanding Pipeline SUMMARY: Exelixis, currently known for its single marketed drug, Cabometyx (cabozantinib), is strateg...
Upfront Modified FOLFOXIRI Plus Panitumumab for RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Final Results of the Phase III TRIPLETE Study
TITLE: Upfront mFOLFOXIRI Plus Panitumumab for RAS/BRAF Wild-Type Metastatic Colorectal Cancer: TRIPLETE Study Final Results SUMMARY: The phase III TRIPLETE study demonstrates that upfront modified FO...
Anbenitamab in previously treated HER2-positive gastric cancer (KC-WISE): pre-specified interim analysis of a randomized, phase III clinical trial
TITLE: Anbenitamab for Previously Treated HER2-Positive Gastric Cancer: Interim Analysis of Phase III KC-WISE Trial SUMMARY: A pre-specified interim analysis of the randomized, phase III KC-WISE trial...
FDA loosens AI oversight: What clinicians need to know about the 2026 guidance
TITLE: FDA Revises AI Oversight for Clinical Decision Support: Implications for Clinicians SUMMARY: The FDA announced revised guidance in 2026, significantly loosening oversight for certain AI-enabled...
HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination With Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer
TITLE: HER2CLIMB-05: Tucatinib, Trastuzumab, and Pertuzumab as First-Line Maintenance for HER2+ Metastatic Breast Cancer SUMMARY: The HER2CLIMB-05 study is a Phase III, randomized, double-blind, place...
A Deep Prostate-specific Antigen Response to Darolutamide plus Androgen Deprivation Therapy Is Associated with Better Clinical Outcomes in the Phase 3 ARANOTE Trial in Patients with Metastatic Hormone-sensitive Prostate Cancer
TITLE: Deep PSA Response to Darolutamide + ADT Linked to Improved Outcomes in mHSPC: ARANOTE Trial SUMMARY: A post-hoc analysis of the Phase 3 ARANOTE trial, published in European Urology Oncology, in...
Capivasertib plus paclitaxel as first-line treatment for metastatic triple-negative breast cancer: Results from the randomised, global phase III CAPItello-290 trial
TITLE: CAPItello-290: Capivasertib Plus Paclitaxel in First-Line Metastatic Triple-Negative Breast Cancer SUMMARY: The CAPItello-290 trial, a global, randomized Phase III study, investigated the effic...
Opportunities for Harmonization of US Food and Drug Administration Regulatory Decisions Exemplified by the Traditional Approval of Sotorasib and Panitumumab for Colorectal Cancer
TITLE: FDA Regulatory Harmonization Opportunities: Sotorasib and Panitumumab in Colorectal Cancer SUMMARY: This analysis, published in the Journal of Clinical Oncology, highlights opportunities for ha...
Neutropenic diet best during blood cancer treatment
TITLE: Neutropenic Diet Reduces Infection Risk in Blood Cancer Patients Undergoing Intensive Treatment SUMMARY: A randomized phase 3 noninferiority trial indicates that a neutropenic diet significantl...
Self-reported unmet care needs in daily activities among community-dwelling older adults with cancer: Analyses from the 2015–2019 National Health and Aging Trends Study
TITLE: Unmet Care Needs in Older Adults with Cancer: Insights from National Health and Aging Trends Study SUMMARY: A retrospective analysis of the 2015-2019 National Health and Aging Trends Study (NHA...
[Articles] Aumolertinib as adjuvant therapy in resected EGFR-mutated non-small-cell lung cancer (ARTS): a double-blind, multicentre, randomised, controlled, phase 3 trial
TITLE: Aumolertinib Adjuvant Therapy for Resected EGFR-Mutated NSCLC: Phase 3 ARTS Trial Results SUMMARY: The phase 3 ARTS trial demonstrated significant clinical benefits of aumolertinib as adjuvant ...
